Variable | Categorisation | FOXM1 immunoreactivity | |||
---|---|---|---|---|---|
n analysable | negativeb | positiveb | pc | ||
Clinicopathological data: | |||||
Tumour stagea | |||||
pT1 | 61 | 18 | 43 | 0.339 | |
pT2 | 96 | 27 | 69 | ||
pT3 | 14 | 1 | 13 | ||
pT4 | 28 | 9 | 19 | ||
Lymph node statusa | |||||
pN0 | 55 | 28 | 61 | 0.425 | |
pN1-3 | 139 | 27 | 78 | ||
Histological grade | |||||
G1 | 22 | 10 | 12 | 0.146 | |
G2 | 90 | 25 | 65 | ||
G3 | 87 | 21 | 66 | ||
Multifocality | |||||
unifocal tumour | 174 | 48 | 126 | 0.820 | |
multifocal tumour | 27 | 8 | 19 | ||
Histological type | |||||
ductal | 165 | 48 | 117 | 0.133 | |
lobular | 15 | 1 | 14 | ||
other | 18 | 6 | 12 | ||
Immunohistochemistry (IHC): | |||||
Oestrogen receptor status | |||||
negative | 57 | 9 | 48 | 0.085 | |
positive | 103 | 29 | 74 | ||
Progesterone receptor status | |||||
negative | 115 | 27 | 88 | 0.702 | |
positive | 53 | 14 | 39 | ||
HER2 status | |||||
weak (0–2+) | 154 | 45 | 109 | 0.045 | |
strong (3+) | 18 | 1 | 17 |